Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.20
Ask:
1.40
Spread: 0.20 (16.667%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Update on CFO Appointment

29 Nov 2016 07:00

RNS Number : 3503Q
Genedrive PLC
29 November 2016
 

 

 

For release: 29 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

Update on CFO Appointment

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that, following his appointment as Chief Financial Officer and a Director of the Company as announced on 21 September 2016, Matthew Fowler will join genedrive plc on 13 December 2016.

 

Matthew joins genedrive plc with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive plc, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

 

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

- Ends -

 

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGGUGUPQGMR
Date   Source Headline
10th Sep 20214:35 pmRNSPrice Monitoring Extension
10th Sep 20212:01 pmRNSProposed Placing and Open Offer
31st Aug 20217:00 amRNSNew Genedrive system readied for AIHL launch
1st Jul 20217:00 amRNSGenedrive COVID-19 Point of Care device update
25th Jun 20214:40 pmRNSSecond Price Monitoring Extn
25th Jun 20214:35 pmRNSPrice Monitoring Extension
25th Jun 20211:17 pmRNSGenedrive confirms receipt of India Import License
25th Jun 202111:05 amRNSSecond Price Monitoring Extn
25th Jun 202111:00 amRNSPrice Monitoring Extension
22nd Jun 202111:05 amRNSSecond Price Monitoring Extn
22nd Jun 202111:00 amRNSPrice Monitoring Extension
28th May 20216:00 pmRNSBlock listing Interim Review
28th May 20214:40 pmRNSSecond Price Monitoring Extn
28th May 20214:35 pmRNSPrice Monitoring Extension
6th May 20212:05 pmRNSSecond Price Monitoring Extn
6th May 20212:00 pmRNSPrice Monitoring Extension
30th Apr 20217:00 amRNSCOVID-19 PCR test approved by Indian regulator
23rd Apr 20217:00 amRNSExcellent performance data for Genedrive® HCV test
19th Apr 20217:00 amRNSPHE National Framework Agreement
1st Apr 20217:00 amRNSTotal Voting Rights
31st Mar 202111:05 amRNSSecond Price Monitoring Extn
31st Mar 202111:00 amRNSPrice Monitoring Extension
25th Mar 20217:00 amRNSHalf-year Report
9th Mar 20217:00 amRNSDistribution agreement
3rd Mar 20217:00 amRNSAntibiotic Induced Hearing Loss update
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20217:00 amRNSInvestor Presentation
1st Mar 20217:00 amRNSTotal Voting Rights
17th Feb 20217:00 amRNSFirst US shipments of Genedrive® 96 SARS-CoV-2 Kit
12th Feb 20212:10 pmRNSHolding(s) in Company
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
9th Feb 20212:28 pmRNSHolding(s) in Company
8th Feb 20213:30 pmRNSHolding(s) in Company
8th Feb 202112:51 pmRNSHolding(s) in Company
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20212:05 pmRNSHolding(s) in Company
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20211:22 pmRNSHolding(s) in Company
1st Feb 20219:05 amRNSSecond Price Monitoring Extn
1st Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20219:05 amRNSSecond Price Monitoring Extn
29th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20219:05 amRNSSecond Price Monitoring Extn
28th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNSDistribution agreement with Beckman Coulter

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.